Author

P. C. Mack

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:variant calling· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

D. R. Gandara· 2 shared A. Baca· 1 shared A. K. Simons· 1 shared A. Srivastava· 1 shared A. Talasaz· 1 shared B. J. Sanderson· 1 shared C. G. Tepper· 1 shared C. J. Bult· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. R. Gandara

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Genomically and Clinically Annotated Patient Derived Xenograft (PDX) Resource for Preclinical Research in Non-Small Cell Lung Cancer

X. Y. Woo, A. Srivastava, P. C. Mack, J. H. Graber, B. J. Sanderson, M. W. Lloyd, M. Chen, S. Domanskyi, R. Gandour-Edwards, R. A. Tsai, J. Keck, M. Cheng, M. Bundy, E. L. Jocoy, J. W. Riess, , C. J. Bult

The paper describes a collection of 79 genomically and clinically annotated lung cancer PDX models that retain patient tumor features and treatment responses, available through MMHCdb.

bioRxiv · Mar 6, 2022Cancer Biology

The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients

O. Zill, K. Banks, S. Fairclough, S. Mortimer, J. Vowles, R. Mokhtari, D. R. Gandara, P. C. Mack, J. Odegaard, R. Nagy, A. Baca, H. Eltoukhy, D. Chudova, R. Lanman, A. Talasaz

This study analyzes cfDNA from 21,807 cancer patients to identify actionable genomic alterations and their relationship to treatment and tumor heterogeneity.

bioRxiv · Dec 12, 2017Cancer Biology